To evaluate the effect of MYO1C‐rich EVs mediated by RAB31 on glioma progression, U87MG cells and GSC2 were treated with EVs from control GhECs (siNC), RAB31 knockdown GhEC (siRAB31), or NhECs. Here, RAB31 is linked to glioma.